在EGFR-TKI失败后,针对EGFR突变性NSCLC的晚期化学疗法组合疗法:一个网络元分析
Lan-Lan Pang1, Wei-Tao Zhuang1, Zi-Hong Chen1
1Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong Province, China.
对于在EGFR-TKI上进展的晚期EGFR突变非小细胞肺癌 (NSCLC),amivantamab + 化疗和免疫疗法 + 抗血管生成药物 + 化疗提供了优异的结果. 这些组合比传统化疗更为推,以改善无进展的生存率和反应率.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 传统化疗在EGFR突变非小细胞肺癌 (NSCLC) 后EGFR-氨酸激酶抑制剂 (TKI) 失效后的晚期EGFR突变非小细胞肺癌 (NSCLC) 中显示出有限的疗效.
- 综合治疗策略是必要的,但最佳方案仍在争论中.
研究的目的:
- 为了比较各种基于的化疗方案的疗效和安全性,在EGFR-TKI进展后治疗EGFR突变性NSCLC.
- 为了确定这个患者群体的最佳治疗策略.
主要方法:
- 贝叶斯随机效应网络对9项随机对照试验 (RCT) 的元分析,涉及2534名患者.
- 5种化疗方案的比较:单独的化疗,化疗+免疫疗法,化疗+贝瓦西祖马布,化疗+免疫疗法+抗血管原药,以及化疗+阿米万塔马布.
- 分析无进展生存 (PFS),客观反应率 (ORR) 和与治疗相关的不良事件 (TRAE).
主要成果:
- 与单独化学疗法相比,阿米万他马布+化疗和免疫疗法+抗血管原药+化疗显著改善了PFS和ORR.
- 贝瓦西祖马布 + 化疗显示,进展风险显著降低.
- 化疗 + 免疫治疗提供了适度的PFS益处,但没有改善ORR.
- 阿米万他马布 + 化疗与更高等级的3-5 TRAEs有关.
结论:
- 建议阿米万他马布 + 化疗和免疫治疗 + 抗血管原药 + 化疗作为EGFR-TKI耐药高级NSCLC的首选治疗选择.
- 这些组合提供了卓越的疗效,可能为免疫疗法创造一个治疗窗口.
- 这项研究为晚期EGFR突变性NSCLC提供了最新的治疗方法.
更多相关视频
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Cancer Survival Analysis
Mitogens and the Cell Cycle
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
